Neurocrine Biosciences (NBIX)
Health Care
Neurocrine is a profitably growing, neuroscience-focused biotech commercializing novel treatments for movement disorders, endocrine diseases, and psychiatric conditions with expanding late-stage pipeline and recent M&A.
What Neurocrine Biosciences does
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders. The company markets FDA-approved treatments including INGREZZA (valbenazine) for tardive dyskinesia and Huntington's disease chorea, CRENESSITY (crinecerfont) for congenital adrenal hyperplasia, and collaborates with AbbVie on endometriosis and uterine fibroids therapies. Its pipeline includes multiple compounds in mid- to late-phase development across diverse modalities including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies.
Themes: ["movement disorders / tardive dyskinesia","Huntington's disease","endocrine disorders / congenital adrenal hyperplasia (CAH)","psychiatric disorders / schizophrenia","endometriosis / uterine fibroids","VMAT2 biology","rare disease","neuroscience-focused drug development"]
Fundamentals
- Price$180.55 as of 2026-07-09 close
- Market cap$17.9B as of 2026-07-10
- 1-year return+35.2% as of 2026-07-09 close
- P/E26.84 as of 2026-07-10
- Net margin+21.6% as of 2026-07-10
- Gross margin+98.2% as of 2026-07-10
- ROE+21.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+28.6% as of 2026-07-10
- Revenue CAGR (3y)+24.3% SEC XBRL
- Beta0.39 as of 2026-07-10
Key risks (from latest filing)
["Dependence on limited commercial product portfolio: INGREZZA accounted for a significant portion of total net product sales ($2.51 billion in 2025), creating concentration risk if adoption slows or competitive pressures emerge","Clinical development and regulatory uncertainty: Multiple mid- to late-phase compounds in development may fail to achieve clinical efficacy or gain regulatory approval, impacting future revenue growth","Large acquisition integration risk: The pending $2.9 billion acquisition of Soleno Therapeutics requires successful integration, regulatory approval, and operational execution to realize anticipated value"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.